Novasep to Build the World's Largest Chromatography Plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novasep to Build the World's Largest Chromatography Plant


ePT--the Electronic Newsletter of Pharmaceutical Technology

Novasep announced that it will be investing EUR 30 million ($39 million) to build what will be the world’s largest chromatography plant for the production of large volumes of commercial APIs. The plant will be built on Novasep’s existing site in Mourenx, France, and is expected to be operational and validated within 18 months. According to the company’s press release, the new plant, designed by an in-house engineering team, will contain Varicol continuous chromatography systems with 1200-mm diameter columns operated at up to 70 bars. The plant will enable the production of a highly purified API from a complex mixture. In addition, the systems will integrate sophisticated solvent recovery systems for the recycling of 99.9% of solvents.

According to the press release, the chromatography plant is the third in a string of global investments by Novasep. The first was the opening of a 2000-m2 facility in Shanghai, China and the second was a EUR three million ($3.9 million) investment to expand the highly potent API manufacturing capabilities at Novasep’s facility in Le Mans, France. “Demand for Novasep’s advanced, purification-based manufacturing capabilities in the life-science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third and largest global plant expansion in 2012,” said Patrick Glaser, president and CEO of Novasep, in the release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
12%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here